{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:12:37Z","timestamp":1787317957652,"version":"build-2736575974"},"reference-count":61,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Environ Pathol Toxicol Oncol"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>Prostate cancer and inflammation mechanism are closely related because chronic inflammation causes inflammatory cells to infiltrate into prostatic atrophy areas and proliferative inflammatory atrophy is accepted as the initiator of prostate cancer. The study included 90 patients (28 patients with benign prostatic hyperplasia (BPH), 35 patients with localized prostate cancer (LPCa), and 27 patients with metastatic prostate cancer (MPCa) and 90 healthy controls. Blood samples from 90 patients and 90 healthy people were used to isolate genomic DNA. Serum protein levels were detected using the ELISA technique, and genotyping was done using the PCR-RFLP method. It was found that genotype distributions of CCR3 gene rs4987053 and the COX-2 gene rs689466 variants showed a substantial difference between the groups (Control, BPH, LPCa, MPCa) (respectively &lt;i&gt;P&lt;\/i&gt; &amp;#60; 0.05, &lt;i&gt;P&lt;\/i&gt; &amp;#60; 0.001). In addition, a important difference was determined between the non-cancerous and the prostate cancer groups in the NOD1 gene rs5743336 variant genotype distributions (&lt;i&gt;P&lt;\/i&gt; &amp;#60; 0.05). However, no substantial relationship was determined between the rs16969415, rs1801157, rs2228014, rs2066847, rs4986791 variants, and a risk of prostate cancer. The serum IL-1&amp;beta;, LY96, and TLR4 protein levels differed significantly between the groups (Control, BPH, LPCa, MPCa) (&lt;i&gt;P&lt;\/i&gt; &amp;#60; 0.001). In addition, IL-1&amp;beta; was associated with rs689466, LY96 with rs2228014, rs5743336 genotypes (&lt;i&gt;P&lt;\/i&gt; &amp;#60; 0.05). As a conclusion, the CCR3 gene rs4987053, COX-2 gene rs689466, and NOD1 gene rs5743336 variations were determined to be closely associated with prostate cancer risk.<\/p>","DOI":"10.1615\/jenvironpatholtoxicoloncol.2024054333","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T16:14:30Z","timestamp":1729872870000},"page":"27-49","source":"Crossref","is-referenced-by-count":2,"title":["Inflammatory Gene Variants and Protein Levels: An Important Predictor of Prostate Cancer Development"],"prefix":"10.1615","volume":"44","author":[{"given":"Emine","family":"Yagci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulyam","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Ozbayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertugrul","family":"Colak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Daniyal M, Siddiqui ZA, Akram M, Asif H, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15(22): 9575-8.","DOI":"10.7314\/APJCP.2014.15.22.9575"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11(2):1388-413.","DOI":"10.2741\/1891"},{"key":"4","unstructured":"Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology, E-book: Vol. 4 set. Elsevier Health Sciences; 2015."},{"key":"5","doi-asserted-by":"crossref","unstructured":"English HF, Santen RJ, Lsaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate. 1987;11(3):229-42.","DOI":"10.1002\/pros.2990110304"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994;78(6):1536-9.","DOI":"10.1210\/jcem.78.6.7515392"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Elgamal A-AA, Ectors NL, Sunardhi-Widyaputra S, Van Poppel HP, Van Damme BJ, Baert LV. Detection of prostate specific antigen in pancreas and salivary glands: A potential impact on prostate cancer overestimation. J Urol. 1996;156(2):464-8.","DOI":"10.1016\/S0022-5347(01)65883-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Elgamal AA, Van de Voorde W, Van Poppel H, Lauweryns J, Baert L. Immunohistochemical localization ofprostate-specific markers within the accessory male sex glands of Cowper, Littre, and morgagni. Urology. 1994;44(1):84-90.","DOI":"10.1016\/S0090-4295(94)80014-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Howarth D, Aronson I, Diamandis E. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer. 1997;75(11):1646-51.","DOI":"10.1038\/bjc.1997.280"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Remmers S, Roobol MJ. Personalized strategies in population screening for prostate cancer. Int J Cancer. 2020;147(11):2977-87.","DOI":"10.1002\/ijc.33045"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Ozbayer C, Kurt H, Bayramoglu A, Gunes HV, Metintas M, Degirmenci I, Oner KS. The role of NOD1\/CARD4 and NOD2\/CARD15 genetic variations in lung cancer risk. Inflamm Res. 2015;64(10):775-9.","DOI":"10.1007\/s00011-015-0859-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Klink JC, Ba\u00f1ez LL, Gerber L, Lark A, Vollmer RT, Freedland SJ. Intratumoral inflammation is associated with more aggressive prostate cancer. World J Urol. 2013;31(6):1497-503.","DOI":"10.1007\/s00345-013-1065-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Elkahwaji JE. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol. 2013;5:1-10.","DOI":"10.2147\/RRU.S23386"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Ou T, Lilly M, Jiang W. The pathologic role of toll-like receptor 4 in prostate cancer. Front Immunol. 2018;9:1188.","DOI":"10.3389\/fimmu.2018.01188"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Ho D-R. Prostate inflammation: A brief review. Urol Sci. 2017;28(3):113-8.","DOI":"10.1016\/j.urols.2017.04.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kang MJ, Heo SK, Song EJ, Kim DJ, Han SY, Han JH, Kim BY, Park JH. Activation of Nod1 and Nod2 induces innate immune responses of prostate epithelial cells. Prostate. 2012;72(12):1351-8.","DOI":"10.1002\/pros.22483"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Haverkamp J, Charbonneau B, Ratliff TL. Prostate inflammation and its potential impact on prostate cancer: A current review. J Cell Biochem. 2008;103(5):1344-53.","DOI":"10.1002\/jcb.21536"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Kutikhin AG, Yuzhalin AE. Genomics of pattern recognition receptors: Applications in oncology and cardiovascular diseases. New York: Springer Science & Business Media; 2013.","DOI":"10.1007\/978-3-0348-0688-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Zhang K, Zhou B, Wang Y, Rao L, Zhang L. The TLR4 gene polymorphisms and susceptibility to cancer: A systematic review and meta-analysis. Eur J Cancer. 2013;49(4):946-54.","DOI":"10.1016\/j.ejca.2012.09.022"},{"key":"20","unstructured":"Tuere-Oezdemir F, Gazouli M, Tzivras M, Panagos C, Bovaretos N, Petraki K, G\u00c4\u00b1annakopoulos A, Korkolopoulou P, Mantzaris GJ. Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Anticancer Res. 2008;28(6A):3697-700."},{"key":"21","doi-asserted-by":"crossref","unstructured":"Kurt H, Ozbayer C, Bayramoglu A, Gunes HV, Degirmenci \u0130, Oner KS, Metintas M. Determination of the relationship between rs4986790 and rs4986791 variants of TLR4 gene and lung cancer. Inflammation. 2016;39(1):166-71.","DOI":"10.1007\/s10753-015-0235-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Degirmenci I, Ozbayer C, Kebapci MN, Kurt H, Colak E, Gunes HV. Common variants of genes encoding TLR4 and TLR4 pathway members TIRAP and IRAK1 are effective on MCP1, IL6, IL1\u00ce\u00b2, and TNF\u00ce\u00b1 levels in type 2 diabetes and insulin resistance. Inflamm Res. 2019;68(9):801-14.","DOI":"10.1007\/s00011-019-01263-7"},{"key":"23","unstructured":"Ozbayer C, Kebapci MN, Yagci E, H\u00fclyam K, G\u00fcnes HV, De\u011firmenci \u0130. The rs4925648, rs121908149 and rs121908152 genetic variations in the NLRP3 inflammasome and risk of type 2 diabetes. Osmangazi Journal of Medicine. 2019;41(2):153-60."},{"key":"24","doi-asserted-by":"crossref","unstructured":"Ozbayer C, Kebapci MN, Degirmenci I, Yagci E, Gunes HV, Kurt H. Genetic variant in the 3'-untranslated region of the COX2 gene is associated with type 2 diabetes: A hospital-based case-control study. Prostaglandins Leukot Essent Fatty Acids. 2018;137:39-42.","DOI":"10.1016\/j.plefa.2018.07.012"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Ozbayer C, Kurt H, Kebapci M, Gunes H, Colak E, Degirmenci I. Effects of genetic variations in the genes encoding NOD 1 and NOD 2 on type 2 diabetes mellitus and insulin resistance. J Clin Pharm Ther. 2017;42(1):98-102.","DOI":"10.1111\/jcpt.12482"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I. Inflammation and prostate cancer. Adv Exp Med Biol. 2018;1095:41-65.","DOI":"10.1007\/978-3-319-95693-0_3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68(3):927-36.","DOI":"10.1158\/0008-5472.CAN-07-2608"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Kang WS, Kim YJ, Park HJ, Kim SK, Paik J-W, Kim JW. Association of CCL11 promoter polymorphisms with schizophrenia in a Korean population. Gene. 2018;656:80-5.","DOI":"10.1016\/j.gene.2018.02.053"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Kochetova OV, Avzaletdinova DS, Morugova TV, Mustafina OE. Chemokine gene polymorphisms association with increased risk of type 2 diabetes mellitus in Tatar ethnic group, Russia. Mol Biol Rep. 2019;46(1):887-96.","DOI":"10.1007\/s11033-018-4544-6"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Fukunaga K, Asano K, Mao XQ, Gao PS, Roberts M, Oguma T, Shiomi T, Kanazawa M, Adra CN, Shirakawa T, Hopkin JM, Yamaguchi K. Genetic polymorphisms of CC chemokine receptor 3 in Japanese and British asthmatics. Eur Respir J. 2001;17(1):59-63.","DOI":"10.1183\/09031936.01.17100590"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Breunis W, Biezeveld M, Geissler J, Kuipers I, Lam J, Ottenkamp J, Hutchinson A, Welch R, Chanock SJ, Kuijpers TW. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin Exp Immunol. 2007;150(1):83-90.","DOI":"10.1111\/j.1365-2249.2007.03457.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Ishida Y, Kido A, Akahane M, Kishi S, Tsukamoto S, Fujii H, Honoki K, Tanaka Y. Mesenchymal stem cells up-regulate the invasive potential of prostate cancer cells via the eotaxin-3\/CCR3 axis. Pathol Res Pract. 2018;214(9):1297-302.","DOI":"10.1016\/j.prp.2018.06.012"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA; Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM,Cunningham JM, Hartmann LC. Inherited determinants of ovarian cancer survival inherited determinants of ovarian cancer survival. Clin Cancer Res. 2010;16(3):995-1007.","DOI":"10.1158\/1078-0432.CCR-09-2553"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Tong X, Ma Y, Deng H, Wang X, Liu S, Yan Z, Peng S, Fan H. The SDF-1 rs1801157 polymorphism is associated with cancer risk: An update pooled analysis and FPRP test of 17,876 participants. Sci Rep. 2016;6:27466.","DOI":"10.1038\/srep27466"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, Tanaka Y, Dahiya R. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 2007;13(17):5056-62.","DOI":"10.1158\/1078-0432.CCR-07-0859"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Petersen DC, Severi G, Hoang HN, Padilla EJ, Southey MC, English DR, Hopper JL, Giles GG, Hayes VM. No association between common chemokine and chemokine receptor gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3615-7.","DOI":"10.1158\/1055-9965.EPI-08-0896"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Sbrissa D, Semaan L, Govindarajan B, Li Y, Caruthers NJ, Stemmer PM, Cher ML, Sethi S, Vaishampayan U, Shisheva A, Chinni SR. A novel cross-talk between CXCR4 and PI4KIII\u00ce\u00b1 in prostate cancer cells. Oncogene. 2019;38(3):332-44.","DOI":"10.1038\/s41388-018-0448-0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Wu Y, Zhang C, Xu W, Zhang J, Zheng Y, Lu Z, Liu D, Jiang K. CXC motif chemokine receptor 4 gene polymorphism and cancer risk. Medicine. 2016;95(49):e5317.","DOI":"10.1097\/MD.0000000000005317"},{"key":"39","doi-asserted-by":"crossref","unstructured":"McGovern DP, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, Cookson WOC, Jewell DP. Association between a complex insertion\/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 2005;14(10):1245-50.","DOI":"10.1093\/hmg\/ddi135"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, G\u00fcnther S, Prescott NJ, Onnie CM, H\u00e4sler R, Sipos B, F\u00f6lsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39(2):207-11.","DOI":"10.1038\/ng1954"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Molnar T, Hofner P, Nagy F, Lakatos PL, Fischer S, Lakatos L, Kovacs A, Altorjay I, Papp M, Palatka K, Demeter P, Tulassay Z, Nyari T, Miheller P, Papp J, Mandi Y, Lonovics J, the Hungarian IBD Study Group 1. NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2\/CARD15 in Hungarian patients with Crohn's disease. Dig Liver Dis. 2007;39(12):1064-70.","DOI":"10.1016\/j.dld.2007.09.003"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Tanabe T, Ishige I, Suzuki Y, Aita Y, Furukawa A, Ishige Y, Uchida K, Suzuki T, Takemura T, Ikushima S, Oritsu M, Yokoyama T, Fujimoto Y, Fukase K, Inohara N, Nunez G, Eishi Y. Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. Biochim Biophys Acta Mol Basis Dis. 2006;1762(9):794-801.","DOI":"10.1016\/j.bbadis.2006.07.006"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Forrest MS, Skibola CF, Lightfoot TJ, Bracci PM, Willett EV, Smith MT, Holly EA, Roman E. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol. 2006;134(2):180-3.","DOI":"10.1111\/j.1365-2141.2006.06141.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, Juozaityte E, Kiudelis G, Jonaitis L, Malfertheiner P. Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS\/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet. 2011;12:112.","DOI":"10.1186\/1471-2350-12-112"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Lubi\u0144ski J, Huzarski T, Kurzawski G, Suchy J, Masoj\u0107 B, Mierzejewski M, Lener M, Domagala W, Chosia M, Teodorczyk U, M\u00c4\u0099drek K, D\u00c4\u0099bniak T, Z\u00c5\u0082owocka E, Gronwald J, Byrski T, Grabowska E, Nej K, Szyma\u00c5\u0084ska A, Szyma\u00c5\u0084ska J, Matyjasik J, Cybulski C, Jakubowska A, G\u00f3rski B, Narod SA. The 3020insC allele of NOD2 predisposes to cancers of multiple organs. Hered Cancer Clin Pract. 2005;3(2):1-5.","DOI":"10.1186\/1897-4287-3-2-59"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Mukherjee S, Siddiqui MA, Dayal S, Ayoub YZ, Malathi KJJoir. Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells. J Inflamm Res. 2014;7:89-101.","DOI":"10.2147\/JIR.S61365"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Balistreri C, Caruso C, Carruba G, Miceli V, Campisi I, List F, Lio D, Colonna-Romano G, Candore G. A pilot study on prostate cancer risk and pro-inflammatory genotypes: Pathophysiology and therapeutic implications. Curr Pharm Des. 2010;16(6):718-24.","DOI":"10.2174\/138161210790883877"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Cheng I, Liu X, Plummer S, Krumroy L, Casey G, Witte J. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97(4):557-61.","DOI":"10.1038\/sj.bjc.6603874"},{"key":"49","unstructured":"Wu HC, Chang CH, Ke HL, Chang WS, Cheng HN, Lin HH, Wu CY, Tsai CW, Tsai RY, Lo WC, Bau DT. Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan. Anticancer Res. 2011;31(1):221-5."},{"key":"50","doi-asserted-by":"crossref","unstructured":"Sugie S, Tsukino H, Mukai S, Akioka T, Shibata N, Nagano M, Kamoto T. Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men. Tumour Biol. 2014;35(3):2717-21.","DOI":"10.1007\/s13277-013-1358-y"},{"key":"51","unstructured":"Taheri M, Noroozi R, Rakhshan A, Ghanbari M, Omrani MD, Ghafouri-Fard S. IL-6 genomic variants and risk of prostate cancer. Urol J. 2018;16(5):463-8."},{"key":"52","doi-asserted-by":"crossref","unstructured":"El-Omar EM, Carrington M, Chow W-H, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776): 398-402.","DOI":"10.1038\/35006081"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M. Interleukin-1B gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003;37(1):65-71.","DOI":"10.1053\/jhep.2003.50017"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 B gene are associated with increased risk of non-small cell lung cancer. Int J Cancer. 2004;109(3):353-6.","DOI":"10.1002\/ijc.11695"},{"key":"55","unstructured":"Yencilek F, Yildirim A, Yilmaz SG, Altinkilic EM, Dalan AB, Bastug Y, Isbir T. Investigation of interleukin-1B polymorphisms in prostate cancer. Anticancer Res. 2015;35(11):6057-61."},{"key":"56","doi-asserted-by":"crossref","unstructured":"Bedini N, Cicchetti A, Palorini F, Magnani T, Zuco V, Pennati M, Campi E, Allavena P, Pesce S, Villa S, Avuzzi B, Morlino S, Visentin ME, Zaffaroni N, Rancati T, Valdagni R. Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy. Dis Markers. 2018;2018:9128128.","DOI":"10.1155\/2018\/9128128"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE, Ottewell PD. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: Evidence using a novel bone-seeking cell line. Endocr Relat Cancer. 2014;21(2):327-41.","DOI":"10.1530\/ERC-13-0158"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Halvorsen OJ, Oyan AM, Bo TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, Lin B, Jonassen I, Hood L, Akslen LA, Kalland KL. Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. Int J Oncol. 2005;26(2):329-36.","DOI":"10.3892\/ijo.26.2.329"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Hua D, Liu MY, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 2009;46(15):2876-84.","DOI":"10.1016\/j.molimm.2009.06.016"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Paarnio K, Tuomisto A, V\u00e4yrynen SA, V\u00e4yrynen JP, Klintrup K, Ohtonen P, M\u00e4kinen MJ, M\u00e4kel\u00e4 J, Karttunen TJ. Serum TLR2 and TLR4 levels in colorectal cancer and their association with systemic inflammatory markers, tumor characteristics, and disease outcome. Apmis. 2019;127(8):561-9.","DOI":"10.1111\/apm.12971"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C, Michel-Schmidt R, Kirkpatrick CJ. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int J Mol Med. 2007;20(1):21-9.","DOI":"10.3892\/ijmm.20.1.21"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Sadi MV. PSA screening for prostate cancer. Rev Assoc Med Bras. 2017;63:722-5.","DOI":"10.1590\/1806-9282.63.08.722"}],"container-title":["Journal of Environmental Pathology, Toxicology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/752a758c260dbddf\/JEP(T)-54333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T06:48:34Z","timestamp":1756536514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/0ff459a57a4c08d0,7f8ae079718bb327,752a758c260dbddf.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/jenvironpatholtoxicoloncol.2024054333","relation":{},"ISSN":["0731-8898"],"issn-type":[{"value":"0731-8898","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}